

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

-----X

In re

CERTA DOSE INC.,

Case No. 21-11045-lgb

Debtor.

Chapter 11

-----X

**NOTICE OF FILING OF PROPOSED FINAL BUDGET IN SUPPORT OF PROPOSED  
ORDER GRANTING DEBTOR'S EMERGENCY MOTION (1) AUTHORIZING POST-  
PETITION INTERIM FINANCING FROM DR. CALEB S. HERNANDEZ (DR.  
HERNANDEZ") AND AUTHORIZING USE OF CASH COLLATERAL; (2)  
SCHEDULING A HEARING ON THE FINAL REQUEST FOR THE USE OF CASH  
COLLATERAL; (3) SCHEDULING A HEARING ON THE REQUEST FOR A  
FINAL ORDER APPROVING POST-PETITION FINANCING; (4); AND (5)  
GRANTING SUCH OTHER AND FURTHER RELIEF AND IS DEEMED  
APPROPRIATE ("MOTION")**

*Please be advised* that a final hearing on the Motion is presently scheduled to be heard by  
the Hon. Lisa G. Beckerman, U.S. Bankruptcy Judge, on November 8, 2021 at 10:00 a.m., to  
consider the Debtor's request for the entry of a final order granting the Motion.

*Please be further advised* that attached hereto is a proposed final budget that shall be  
presented to the Court in support of the Debtor's request for the entry of a final order approving  
the Motion.

Dated: New York, New York  
October 21, 2021

/s/Norma E. Ortiz  
Norma E. Ortiz, Esq.  
Ortiz & Ortiz, L.L.P.  
287 Park Avenue South, Ste. 213  
New York, New York 10010  
Tel. (718) 522-1117  
Counsel to the Debtor

**Proposed Final Budget**

**Certa Dose, Inc.**  
*Budget*

	21-Oct	21-Nov	21-Dec	22-Jan	22-Feb	22-Mar
<b>INCOME STATEMENT</b>						
<b>Revenues</b>						
<b>Product 1: EPI</b>						
Case Sales (5 eaches)	50	80	90	90	150	165
Net Selling Price/Case	380	380	380	380	380	380
Net Revenue	<b>19,000</b>	<b>30,400</b>	<b>34,200</b>	<b>34,200</b>	<b>57,000</b>	<b>62,700</b>
<b>Product 2: PALS</b>						
Case Sales (4 eaches)	70	80	90	100	110	120
Net Selling Price/Case	230	230	230	230	230	230
Net Revenue	<b>16,100</b>	<b>18,400</b>	<b>20,700</b>	<b>23,000</b>	<b>25,300</b>	<b>27,600</b>
<b>Product 4: Tape</b>						
Unit Sales	80	100	110	120	190	200
Net Selling Price/Each	10	10	10	10	10	10
Net Revenue	<b>800</b>	<b>1,000</b>	<b>1,100</b>	<b>1,200</b>	<b>1,900</b>	<b>2,000</b>
<b>Product 5: App</b>						
Unit Sales		100	200	300	400	600
Net Selling Price/Each		19.99	19.99	19.99	19.99	19.99
Net Revenue	-	<b>1,999</b>	<b>3,998</b>	<b>5,997</b>	<b>7,996</b>	<b>11,994</b>
<b>Consulting/Upfront</b>						
Loan						
Consulting						
Upfront/Milestone						
Net Revenue	-	-	-	-	-	-
<b>Royalties</b>						
Project X				30,000	35,000	40,000
Net Revenue	-	-	-	30,000	35,000	40,000
<b>Total Product Revenue</b>	<b>35,900</b>	<b>51,799</b>	<b>59,998</b>	<b>64,397</b>	<b>92,196</b>	<b>104,294</b>
<b>Total Net Revenue</b>	<b>35,900</b>	<b>51,799</b>	<b>59,998</b>	<b>94,397</b>	<b>127,196</b>	<b>144,294</b>
<b>Cost of Sales</b>						
<b>Product 1: Epi</b>						
Case Sales	90	100	120	140	200	250
Cost Per Case	98	98	98	98	98	98
Total Cost of Sales	8,820	9,800	11,760	13,720	19,600	24,500
<i>Gross Margin</i>	<i>54%</i>	<i>68%</i>	<i>66%</i>	<i>60%</i>	<i>66%</i>	<i>61%</i>

**Product 2: PALS**

Case Sales	80	90	100	120	140	150
Cost Per Case	54	54	54	54	54	54
Total Cost of Sales	4,307	4,845	5,384	6,461	7,537	8,076
Gross Margin	77%	77%	77%	77%	77%	77%

**Product 4: Tape**

Sales (Eaches)	80	100	110	120	190	200
Cost Per Each	2	2	2	2	2	2
Total Cost of Sales	198	247	272	297	470	495
Gross Margin	75%	75%	75%	75%	75%	75%

**Product 5: App**

Sales (Eaches)	-	50	60	70	100	150
Cost Per Each	2	6	6	6	6	6
Total Cost of Sales	-	300	360	420	600	900
Gross Margin		85%	91%	93%	92%	92%

Sterilization

<b>Total Cost of Sales</b>	<b>13,325</b>	<b>15,193</b>	<b>17,776</b>	<b>20,897</b>	<b>28,207</b>	<b>33,970</b>
<b>Gross Profit</b>	<b>22,575</b>	<b>36,606</b>	<b>42,222</b>	<b>73,500</b>	<b>98,989</b>	<b>110,324</b>
Gross Margin	63%	71%	70%	78%	78%	76%

**Operating Expenses**

**R&D**

**R&D**

-	-	-	-	-	-	-
---	---	---	---	---	---	---

**SALES AND MARKETING**

Advertising Expense	500	500	500	500	500	500
Salaries & Commission						
Travel & Conferences						
Other - Sales &	500	500	1,000	1,000	1,000	1,000

**SALES AND MARKETING**

<b>1,000</b>	<b>1,000</b>	<b>1,500</b>	<b>1,500</b>	<b>1,500</b>	<b>1,500</b>	<b>1,500</b>
--------------	--------------	--------------	--------------	--------------	--------------	--------------

**GENERAL AND ADMINISTRATIVE**

Professional	8,000	8,000	8,000	8,000	8,000	8,000
Legal Legal	10,000	10,000	10,000	10,000	10,000	10,000
IT	800	800	800	800	800	800
Rent and Utilities Expense	1,283	1,283	1,283	1,283	1,283	1,283
Insurance-General	4,000	4,000	4,000	4,000	4,000	4,000
Shipping, Freight and Delivery	500	500	500	500	500	500
Consulting	8,000	8,000	8,000	8,000	8,000	8,000
Other Trustee Fee	500	500	500	500	500	500

	<b>Total G&amp;A</b>	<b>33,083</b>	<b>33,083</b>	<b>33,083</b>	<b>33,083</b>	<b>33,083</b>	<b>33,083</b>
<b>Total OpEx -- Excl Payroll</b>		<b>34,083</b>	<b>34,083</b>	<b>34,583</b>	<b>34,583</b>	<b>34,583</b>	<b>34,583</b>
<b>Payroll</b>		28,000	28,000	28,000	28,000	28,000	28,000
<b>OpEx + Payroll</b>		<b>62,083</b>	<b>62,083</b>	<b>62,583</b>	<b>62,583</b>	<b>62,583</b>	<b>62,583</b>
<b>EBITDA</b>		<b>-39,508</b>	<b>-25,477</b>	<b>-20,361</b>	<b>10,917</b>	<b>36,406</b>	<b>47,741</b>
Compensation expense		7,500	7,500	7,500	7,500	7,500	7,500
Depreciation		-	-	-	-	-	-
Amortization		3,000	3,000	3,000	3,000	3,000	3,000
<b>EBIT</b>		<b>-50,008</b>	<b>-35,977</b>	<b>-30,861</b>	<b>417</b>	<b>25,906</b>	<b>37,241</b>
Interest Income		-300	-300	-300	-300	-300	-300
Other Income							
Interest Expense		-	-	-	-	-	-
<b>EBT</b>		<b>-49,708</b>	<b>-35,677</b>	<b>-30,561</b>	<b>717</b>	<b>26,206</b>	<b>37,541</b>
NOL Ending	<b>-3,524,418</b>	-10,272,287	-10,307,964	-10,338,525	-10,337,808	-10,311,603	-10,274,062
Taxes		-	-	-	-	-	-
<b>Net Income</b>		<b>-49,708</b>	<b>-35,677</b>	<b>-30,561</b>	<b>717</b>	<b>26,206</b>	<b>37,541</b>